Cardiovascular diseases are the leading cause of mortality worldwide, responsible for over 17 million deaths annually according to the World Health Organization (WHO). The aging global population, unhealthy lifestyles, and increasing rates of risk factors such as hypertension, obesity, and diabetes are driving the demand for cardiovascular treatments.
The global cardiovascular small molecule API market is a key sector within the pharmaceutical industry, driven by the growing burden of cardiovascular diseases (CVDs) such as coronary artery disease (CAD), hypertension, heart failure, and arrhythmias. The market is driven by the increasing prevalence of cardiovascular diseases (CVDs), the aging population, and advancements in drug development. Small molecules are the most common type of cardiovascular drugs, and they are designed to interact with specific molecular targets to treat cardiovascular conditions effectively. The market is continuously evolving, driven by various market dynamics such as technological advancements, shifting patient demographics, evolving healthcare needs.
